Risperidone long-acting injection

References

• Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol. Merl 13, 663–670 (1983).
   Google Scholar
• Robinson D, Woerner MG, Alvir JM eta] Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psych. 56, 241–247 (1999).
   PubMed Web of Science ®Google Scholar
• Gaebel W Pietzcker A. Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment. Eur: Arch. Bych. Abutvl. Sri. 235, 45–52 (1985).
   Google Scholar
• Kane JM. Schizophrenia. N Engl. I Merl 334, 34–41 (1996).
   PubMed Web of Science ®Google Scholar
• Davis JM. Maintenance therapy and the natural course of schizophrenia. J: Clin. Psych. 46, 18–21 (1985).
   Google Scholar
• Gitlin M, Nuechterlein K, Subotnik K et al Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset
   Google Scholar
• •• schizophrenia. Am. J. Psychiatry 158, 1835–1842 (2001).
   Google Scholar
• Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 28,266–272 (2002).
   PubMed Web of Science ®Google Scholar
• •Very current review of compliance and impact on treatment.
   Google Scholar
• Lieberman JA, Alvir JM, Koreen A et al Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology14, S13—S21 (1996).
   Web of Science ®Google Scholar
• Davies LM, Drummond ME. Economics and schizophrenia: the real cost. BE J. Fiychiatry25, 18–21 (1994).
   Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 21 (3), 419–429 (1995).
   Google Scholar
• Babiker IE. Noncompliance in schizophrenia. PFchiatr Dev 4,329–337 (1986).
   PubMedGoogle Scholar
• Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. PharmacoEconomics 17,383–389 (2000).
   Google Scholar
• Kane JM, Aguglia E, Altamura AC etal Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference, Siena, Italy. Eur Neuropsychopharmacol 8,55–66 (1998).
   PubMed Web of Science ®Google Scholar
• Walbum J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. BE J. Psychiatry 179,300–307 (2001).
   Google Scholar
• Janssen Pharmaceutica NV. Data on file. October 2001.
   Google Scholar
• Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. DITIF 47,741–773 (1994).
   Google Scholar
• Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. BE j Psychiatry 179, 290–299 (2001).
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl. J. Med. 346, 16–22 (2002).
   PubMed Web of Science ®Google Scholar
• ••Landmark study demonstrating the effectiveness of an atypical antipsychotic in relapse prevention.
   Google Scholar
• Love RC, Conley RR, Kelly DI, eta]. Rehospitalization rates with the atypical antipsychotics in the Maryland mental health system. Schizophr Res. 36,345 (1999).
   Google Scholar
• Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am. J. Health Syst. Pharm. 55, S17—S19 (1998).
   Google Scholar
• Turner M. Long-acting injectable risperidone for schizophrenia. Future Prescriber 3(1), (2002).
   Google Scholar
• Safarti Y, Olivier V, Bouhassira M. The use of new antipsychotics during treatment with schizoprenia — a European enquiry. LEncephale 25,658–666 (1999).
   Google Scholar
• Lasser RA, Ramstack JM, Grandolfi GP, Mannaert E, D'Hoore P Long-acting risperidone (Risperdal Constall : manufacture using Medisorb® microsphere technology, pharmacokinetics, and injection-site assessments. Presented at the 16th Annual Convention of the American Psychiatric Nursing Association, Oct 3–9, TX, USA (2002).
   Google Scholar
• Richelson E, Souder T Binding of antipsychotic drugs to human brain receptors. Life Sci. 68,29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin—dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. PFchiatry55,5–12 (1994).
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. Risperdal ConstaTm. Risperidone long-acting injection. Janssen-Cilag Ltd, NY, USA (2002).
   Google Scholar
• Eerdekens M, Fleischhacker WW, Xie Y etal. Long-term safety and efficacy of Risperdal ConstaTM, the long-acting injection formulation of risperidone. Presented at the XXIII CINP Congress, June 23–27, Montreal, Canada (2002).
   Google Scholar
• Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J. Clin. PFchiatry62, 855–858 (2001).
   PubMed Web of Science ®Google Scholar
• Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P Efficacy and safety of a novel long-acting risperidone microspheres formulation. Presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24—March 1, Davos, Switzerland (2002).
   Google Scholar
• Chue P, Eerdekens M, Augustyns I, Lachaux B, Mokan P, Eriksson L, Pretorius H, David A. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Presented at the 11th Biennial Winter Workshop on Schizophrenia, February 24—March 1, Davos, Switzerland (2002).
   Google Scholar
• Chue P, Devos E, Duchesne I, Leal A, Mehnert A. One-year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Presented at The 7th Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research, May 19–22, Arlington, VA, USA (2002).
   Google Scholar
• Llorca P-M, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Rehospitalization rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Presented at the XXIII CINP Congress, June 23— 27, Montreal, Canada (2002).
   Google Scholar
• Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am. J. Psychiatry 158,266–269 (2001).
   PubMed Web of Science ®Google Scholar
• Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. A117. I Psychiatry 156,863–868 (1999).
   Google Scholar
• Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psych. 36,1283–1294 (1979).
   Google Scholar
• Remington G, Devos E, Eerdekens M, Duchesne I, Leal A, Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use. Presented at the XXHI CINP Congress, June 23–27, Montreal, Canada (2002).
   Google Scholar
• Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. Clin. Psych. 57, 337–345 (1996).
   Google Scholar
• Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. j Gun. PTchopharmacol. 17,298–307 (1997).
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Duchesne I, Mehnert A, Janagap C. Long-acting risperidone improves quality of life. Presented at the XXIII CINP COINIE4 June 23-27, Montreal, Canada (2002).
   Google Scholar
• Freyberger HJ, Eerdekens M, Duchesne I, Mehnert A, Rabinowitz J. Patient satisfaction with their medication during long-term treatment with long-acting risperidone injection. Presented at the XXIII CINP Congress, June 23–27, Montreal, Canada (2002).
   Google Scholar
• Kelleher JP, Centorrino F, Albert J, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs16, 249–261 (2002).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. PFhiatr Serv. 49,196–201 (1998).
   PubMed Web of Science ®Google Scholar
• Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta PFhiatr &and. 102,83–86 (2000).
   Google Scholar
• Schooler NR, Keith SJ, Severe JB etal Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch. Gen. Psych. 54,453–463 (1997).
   PubMed Web of Science ®Google Scholar
• Gaebel W, Janner M, Frommann N etal. First verses multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 53, 145–159 (2002).
   Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psych. 58, 538–546 (1997).
   Google Scholar
• Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol. Med. 33,83–89 (2003).
   Google Scholar
• •Interesting study illustrating physicians' perspectives to treatment.
   Google Scholar
• Peuskens J. Switching approach in the management of schizophrenia patients. Int. Clin. Psychopharmacol 15\(Suppl. 4), S15—S19 (2000).
   Google Scholar
• Hay J. Complications at site of injection of depot neuroleptics. Br M611. 12,421 (1995).
   Google Scholar
• Hogarty GE, Ulrich RE The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J. Psychiatr Res. 32,243–250 (1998).
   PubMed Web of Science ®Google Scholar